Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | GLA | P06280 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | NCOA1 | Q15788 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | NCOA3 | Q9Y6Q9 | 2/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CASP7 | P55210 | 1/20 | 0.43 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | NOS1 | P29475 | 1/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6706482 | 0.98 | KDM4E (0.42) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL222203 | 0.80 | SMN1; SMN2 (0.58) | ALDH1A1GAAHPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL14142068 | 0.80 | ALDH1A1 (0.41) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL1631557 | 0.79 | — | — | |
| SCHEMBL5196234 | 0.79 | FFAR2 (0.40) | KDM4EALDH1A1GLAGAAHPGD | |
| Hydrochloric Acid SCHEMBL7091737 | 0.79 | SMN1; SMN2 (0.56) | ALDH1A1GAAHPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL1107386 | 0.78 | HCAR2 (0.68) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL4292895 | 0.78 | HCAR2 (0.42) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL472995 | 0.78 | CSNK2A2 (0.42) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL12455912 | 0.78 | TP53 (0.44) | KDM4EALDH1A1HPGDCASP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 336 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630528-B2 | Amino aryl derivative useful as diacylglycerol acyltransferase 2 inhibitor and use thereof | LG CHEM, LTD. (KR) | 2026-05-19 | — | — | US | disclosed |
| WO-2025215188-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PKMYT1 | MY-T BIO LIMITED (GB) | 2025-10-16 | — | — | WO | disclosed |
| US-20250243188-A1 | METHIONINE ADENOSYLTRANSERASE 2A INHIBITORS | IDEAYA BIOSCIENCES, INC. | 2025-07-31 | — | — | US | disclosed |
| WO-2025129023-A1 | INDOLE AMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | RECTIFY PHARMACEUTICALS, INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| EP-4071147-B1 | NOVEL AMINO ARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR AND USE THEREOF | LG CHEMICAL LTD (KR) | 2025-03-26 | — | — | EP | disclosed |
| EP-4499630-A1 | BCL-XL INHIBITORS | BeiGene, Ltd. (KY) | 2025-02-05 | — | — | EP | disclosed |
| US-20250034128-A1 | BCL-XL INHIBITORS | BEIGENE, LTD. (KY) | 2025-01-30 | — | — | US | disclosed |
| CN-114846013-B | Novel aminoaryl derivatives useful as diacylglycerol acyltransferase 2 inhibitors and uses thereof | 株式会社LG化学 | 2024-12-20 | — | — | CN | disclosed |
| CN-119060060-A | Imidazole-containing ALK2 kinase inhibitors | 拜奥克里斯特制药公司 | 2024-12-03 | — | — | CN | disclosed |
| CN-118974033-A | Bcl-xL inhibitors | 百济神州有限公司 | 2024-11-15 | — | — | CN | disclosed |
| EP-0006114-B1 | 7-METHOXY-5-OXO-5H-THIAZOLO(2,3-B)QUINAZOLIN-2-CARBOXYLIC ACID AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS, PROCESS FOR THEIR PREPARATION AND MEDICINES CONTAINING THEM | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1982-04-07 | — | — | EP | disclosed |
| US-4316021-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1982-02-16 | — | — | US | disclosed |
| US-4243813-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1981-01-06 | — | — | US | disclosed |
| US-4196125-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1980-04-01 | — | — | US | disclosed |
| EP-0006114-A1 | 7-Methoxy-5-oxo-5H-thiazolo(2,3-b)quinazolin-2-carboxylic acid and its pharmaceutically acceptable salts, process for their preparation and medicines containing them | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1980-01-09 | — | — | EP | disclosed |
| US-4168380-A | ANTIALLERGEN | HOFFMANN-LA ROCHE INC. (US) | 1979-09-18 | — | — | US | disclosed |
| US-4118573-A | ANTIVIRAL AGENTS | ELI LILLY AND COMPANY (US) | 1978-10-03 | — | — | US | disclosed |
| US-4089865-A | Certain thiazole compounds | SYNTEX (U.S.A.) INC. (US) | 1978-05-16 | — | — | US | disclosed |
| US-4018790-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1977-04-19 | — | — | US | disclosed |
| US-4001421-A | THIAZOLE CARDIOVASCULAR AGENTS | SYNTEX (U.S.A.) INC. (US) | 1977-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250243188-A1 | METHIONINE ADENOSYLTRANSERASE 2A INHIBITORS | MAT2A, MAT2B, MAT1A | KDM4E 992/4885ALDH1A1 140/4885GLA 2130/4885 |
| US-20250034128-A1 | BCL-XL INHIBITORS | BCL2, BCL2L1, BCL2L10 | KDM4E 2306/4885ALDH1A1 2996/4885GLA 1074/4885 |
| US-12630528-B2 | Amino aryl derivative useful as diacylglycerol acyltransferase 2 inhibitor and use thereof | DGAT2, DGAT1, SOAT2 | KDM4E 2839/4885ALDH1A1 597/4885GLA 755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.